Estrogen and Platelet Rich Plasma in Treatment of Atrophic Vaginitis

• Status: Not yet recruiting
• Trial end date: 2022-05-01
• Target enrollment: 0
• Participant gender: Female

Summary

This study is designed to compare the efficacy, acceptability, and safety of vaginal estrogen cream and platelet-rich plasma in pt. complaining of atrophic vaginitis.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fayoum University
• Treatments: Estrogens; Estrogens, Conjugated (USP)

Criteria

Inclusion Criteria:

• postmenopausal women aged 50-70 years old

• with a clinical diagnosis of vaginal atrophy who will not need systemic estrogen therapy for the treatment of vasomotor symptoms or prophylaxis of osteoporosis

• Any parity.

Exclusion Criteria:

• Women with any history of carcinoma of the breast or endometrium,

• abnormal genital bleeding, acute thrombophlebitis, or thromboembolic disorders associated with previous estrogen use,

• or current urinary.

• In addition, women who underwent hormone replacement therapy, treated with systemic or vaginal estrogen within 6 months prior to the study,

• or had any contraindication for estrogen therapy will be excluded from the study.